CN1618790A - New Optical active derivative of flavo acidamide, its preparation method and its medicinal composition and use - Google Patents

Abstract

The present invention relates to the stereo-isomers of gamma-lactam (clausenamide) substituted by hydroxyl benzyl group, hydroxyl group and phenyl group, light active stereo-isomers thereof, process for producing same, pharmaceutical composition adopting same as active substances, and therein applications for preparing intelligence promoting and anti-aging pharmaceutical agents.

Description

The optically active derivatives of new Clausenamide, its method for making and its pharmaceutical composition and purposes

Technical field

The present invention relates to the steric isomer of acrinyl, hydroxyl, phenyl replacement gamma-lactam (Clausenamide), the steric isomer that light is lived, and their preparation method are with they pharmaceutical compositions as active substance, urge intelligence, the application of antiaging agent with them in preparation.

Background technology

The mean lifetime of China's population at present surpasses 70 years old, and the average life span during than liberation has increased by one times.External scientific research prediction: during by 2025, the ratio of children below 15 years old will account for 18.6% of total population, and the elderly of 65 years old and over-65s will be above virgin number, reach 18.8%, this numeral shows, surplus 20 year, per 5 philtrums just have 1 the elderly.Degenerative brain disorder (Alzheimer ' s Disease) mostly occurs year surplus 50.The multiple embolism dementia or the senile dementia that cause because of cerebrovascular disease mostly occurred after 60 years old.As seen, because the aging of population, the sickness rate of degenerative brain disorder and senile dementia also will increase.The elderly and distinctive neurodegenerative disorders thereof---various dementias will experience two kinds of death, at first are spiritual death, after be sensual death, suffer untold misery, bring heavy burden more for society and family.Aging population is considered to be only second to war, pestilence, famine, energy resource shortage and influence social development and stabile unfavorable factor.

Control medicament categories old and feeble and the treatment senile dementia is various.Cerebral vasodilator help to provide energy and improve intelligence by improving cerebral blood flow (CBF), but real valuable cerebral vasodilator must have high selectivity, does not influence the brain metabolism, does not have " stealing blood " phenomenon, and platelet aggregation-against and anti thrombotic action are arranged.Though the calcium antagonist nimodipine meets above-mentioned some condition, it only acts on the L-passage in the voltage-dependent ca channel, and N type and T type calcium channel are not had influence.Strengthen in the medicine of choline system function, the Ach precursor only has faint therapeutic action, though Ach receptor stimulant and cholinesterase inhibitor have certain effect, acts on ofer short durationly, and toxic side effect is bigger.Multiple neuropeptide and nerve growth factor once were considered to the hope of treatment dementia, but clinical effectiveness is not good, may be mainly be difficult to enter in the brain and play a role by hemato encephalic barrier owing to this class material, (piracetam is domestic to be produced the 2-Pyrrolidone ethanamide, the trade(brand)name piracetam) after the appearance, belong to the not novel nootropics (nootropil of a class of arguement in early days in the document, this speech be from Greece speech noo (brain) and tropein (to) derivation), reported both at home and abroad in recent years, this medicine slightly or does not still have final conclusion to all types of dysmnesia and senile dementia effect, a major cause is that this medicine is a water-soluble cpds, low by the hemato encephalic barrier rate, be difficult for focusing on target spot and play a role.

The inventor isolates the compound of the gamma-lactam skeleton that contains the piracetam medicine for the first time from rutaceae Calusena lansium [Clausena Lansium (lour.) Skells], be referred to as Clausenamide (Clausenamide).Clausenamide is the gamma-lactam with four chiral centres, and natural product are raceme, and the synthetic method of racemization Clausenamide was once applied for European patent, and its application number is EP0414020, and Chinese patent application is 86107090,90107145.5 and 90107144.7.Left-handed Clausenamide has nootropic effect preferably, the pure substance of this compound, preparation method and potential medical applications inventor patent applied for thereof, CN00124630.5.

4 chiral centres are arranged in the Clausenamide molecule, and the steric isomer that should have 16 light to live is formed 8 pairs of enantiomers of non-enantiomorphic relationship (its configuration and name are as table 1) each other

8 pairs of light of table 1 steric isomer alive

	Clausenamide (I 1) (-)3S，4R，5R，6S (+)3R，4S，5S，6R	Neoclausenamide (I 2) (-)3S，4R，5S，6R (+)3R，4S，5R，6S
			The C6 isomer	Table Clausenamide (I 3) (-)3S，4R，5R，6R (+)3R，4S，5S，6S	Table neoclausenamide (I 4) (-)3S，4R，5S，6S (+)3R，4S，5R，6R
?C 3Isomer (C 3/C 4Cis)	Along Clausenamide (I 5) (+)3S，4S，5S，6R (-)3R，4R，5R，6S	Along neoclausenamide (I 6) (-)3S，4S，5R，6S (+)3R，4R，5S，6R
			Along table Clausenamide (I 7) (+)3S，4S，5S，6S (-)3R，4R，5R，6R	Along table neoclausenamide (I 8) (-)3S，4S，5R，6R (+)3R，4R，5S，6S

A pair of enantiomorph (the I of Clausenamide wherein ₁) inventor's patent applied for (number of patent application: CN00124630.5).Neoclausenamide (the I of racemization ₂) and the table neoclausenamide (I of racemization ₄) be known, the neoclausenamide (I but light is lived ₂) and table neoclausenamide (I ₄) and preparation method thereof do not see bibliographical information.(-) and (+) Clausenamide (I ₁) the inside and outside metabolic result of study of body show: the kind of both metabolites is basic identical, and (-) N-methylol removes methyl yellow skin acid amides [(-)-CM in the metabolite of (-) Clausenamide ₁] and (-)-5-hydroxyl Clausenamide [(-)-CM ₂] content corresponding [(+)-CM in the meta-bolites of (+) Clausenamide ₁] and [(+)-CM ₂] content.The pharmacological testing of its parent (-) Clausenamide shows have tangible nootropic effect, and (+) Clausenamide not to have this effect, and antagonistic action is arranged, and has synthesized metabolite CM in view of the above ₁And CM ₂A pair of enantiomorph and derivative thereof, CM1 wherein ₁The preparation inventor deliver.

Prior art can not be directly used in and prepare have optical activity Clausenamide and derivative thereof of the present invention.

Summary of the invention

The purpose of this invention is to provide the chiral drug Clausenamide derivative that the new light of a class is lived.

Another object of the present invention is to provide the method for preparation optical activity Clausenamide derivative of the present invention;

Another object of the present invention is to provide a kind of new optically active compound () Clausenamide in the short intelligence of preparation, the application of anti-aging effects medicine.

Specifically, the present invention relates to other 14 steric isomers in the Clausenamide light derivative alive shown in general formula (I), form 7 pairs of enantiomers of non-enantiomorphic relationship each other, (its configuration and name are as table 2)

Wherein, the steric configuration of each carbon atom is

I ₂(3R, 4S, 5R, 6S) (+) neoclausenamide

(3S, 4R, 5S, 6R) (-) neoclausenamide

I ₃(3R, 4S, 5S, 6S) (+) table Clausenamide

(3S, 4R, 5R, 6R) (-) table Clausenamide

I ₄(3R, 4S, 5R, 6R) (+) table neoclausenamide

(3S, 4R, 5S, 6S) (-) table neoclausenamide

I ₅(3S, 4S, 5S, 6R) (+) is along Clausenamide

(3R, 4R, 5R, 6S) (-) is along Clausenamide

I ₆(3R, 4R, 5S, 6R) (+) is along neoclausenamide

(3S, 4S, 5R, 6S) (-) is along neoclausenamide

I ₇(3S, 4S, 5S, 6S) (+) is along the table Clausenamide

(3R, 4R, 5R, 6R) (-) is along the table Clausenamide

I ₈(3R, 4R, 5S, 6S) (+) is along the table neoclausenamide

(3S, 4S, 5R, 6R) (-) is along the table neoclausenamide

According to the present invention, also relate to I in the Clausenamide light derivative alive ₂, I ₄, I ₅, I ₆, I ₇And I ₈The preparation method, reaction scheme is as shown in Scheme 1.

Route 1

Wherein:

(a) base catalysis cyclization: available NaOCH ₃, (CH ₃) ₄NOH or lithium diisopropyl amido (LDA);

(b) resolving agent: the amino acid acyl chlorides of (-)-menthol oxygen Acetyl Chloride 98Min., N protection;

(c) protection of hydroxyl, dihydropyrane, Acetyl Chloride 98Min./pyridine or diacetyl oxide/pyridine;

(d) reductive agent of reduction C6 ketone: NaBH ₄Or L-selectride;

(e) reductive agent of reduction C6 ketone: Al (i-C ₃H ₇O) ₃

(f) oxidation C ₃The oxygenant of-OH: K ₂Cr ₂O ₇/ H ⁺, or KMnO ₄+ CuSO ₄, MnO ₂OrDMSO/ (COCl) ₂

(g) reduction Δ ^3,4The reductive agent of two keys: NaBH ₄/ H ⁺, NaBH ₄/ AlCl ₃Or catalytic hydrogenation;

(h) C ₃The configuration inversion of-OH is with azodicarbonic acid diisopropyl ester (DIAD) or azodicarbonic acid diethyl ester (DEAD)/TPP, H ⁺(Mitsunobu method) or finish with CsOAc/18-crown ether-6.

This route is a raw material with N-methyl-N-benzoyl-3-phenyl glycidyl acid amides (A) that known racemization or light are lived all.If the compd A of living with light is a raw material, but then omited steps 2 (b) splits this step.

I in the light of the Clausenamide steric isomer alive in the The compounds of this invention ₃The preparation method of (C6 epimerization body surface Clausenamide) as shown in Scheme 2.

Route 2

The raw material racemization 3-deoxidation table Clausenamide (3-deoxidation-I of this route raw material ₃) be known compound, be the by product of the intermediate [Walfgang Hartwig, Liborrious Born, J.Org, Chem., 1987,52,4352.] of Baeyer pharmaceutical factory synthesising racemation Clausenamide.This route is through compound 3-deoxidation-I ₃Introduce C3 position hydroxyl and obtain racemization table Clausenamide (I ₃).Or fractionation obtains 3-deoxidation-I earlier ₃The light live body, draw hydroxyl then and obtain the table Clausenamide (I that light is lived ₃).

(1) 3-deoxidation table Clausenamide (3-deoxidation-I ₃) 3 hydroxyls of middle introducing, the condition of employing is to be selected from lithium diisopropyl amido (LDA)/O ₂/ triethyl-phosphite (P (OEt) ₃)/hexamethylphosphoramide (HMPT)/THF.

(2) 3-deoxidation table Clausenamide (3-deoxidation-I ₃) fractionation, resolving agent is selected from the amino acid of O-acetyl-R-amygdalic acid, O-acetyl-S-amygdalic acid, menthol fluoroacetic acid, N-protected.

(3) the hydrolysis resolving agent adopts K ₂CO ₃/ CH ₃The condition of OH.

Therefore the present invention also relates to and containing as the The compounds of this invention of active ingredient and the pharmaceutical composition of conventional medicine vehicle or assistant agent.Usually pharmaceutical composition of the present invention contains the The compounds of this invention of 0.1-95 weight %.

The pharmaceutical composition of The compounds of this invention can be according to method preparation well known in the art.When being used for this purpose, if desired, The compounds of this invention and one or more solids or liquid medicine vehicle and/or assistant agent can be combined, make and can be used as suitable administration form or the dosage form that people's medicine or veterinary drug use.

The compounds of this invention or contain its pharmaceutical composition can the unit dosage form administration, route of administration can be enteron aisle or non-enteron aisle, as oral, muscle, subcutaneous, nasal cavity, oral mucosa, skin, peritonaeum or rectum etc., preferred oral.

The compounds of this invention or the route of administration that contains its pharmaceutical composition can be drug administration by injection.Injection comprises intravenous injection, intramuscular injection, subcutaneous injection and intradermal injection etc.

Form of administration can be liquid dosage form, solid dosage.As liquid dosage form can be true solution class, colloidal type, particulate formulations, emulsion dosage form, mixed suspension form.Other formulations are tablet, capsule, dripping pill, aerosol, pill, pulvis, solution, suspensoid, emulsion, granule, suppository, lyophilized injectable powder etc. for example.

The compounds of this invention can be made ordinary preparation, also can be sustained release preparation, controlled release preparation, targeting preparation and various particulate delivery system.

For the unit form of administration is made tablet, can be extensive use of various carrier well known in the art.Example about carrier is, for example thinner and absorption agent are as starch, dextrin, calcium sulfate, lactose, N.F,USP MANNITOL, sucrose, sodium-chlor, glucose, urea, lime carbonate, white bole, Microcrystalline Cellulose, pure aluminium silicate etc.; Wetting agent and tackiness agent are as water, glycerine, polyoxyethylene glycol, ethanol, propyl alcohol, starch slurry, dextrin, syrup, honey, glucose solution, mucialga of arabic gummy, gelatine size, Xylo-Mucine, lac, methylcellulose gum, potassiumphosphate, polyvinylpyrrolidone etc.; Disintegrating agent, for example dry starch, alginates, agar powder, laminaran, sodium bicarbonate and Citric Acid, lime carbonate, polyoxyethylene sorbitol fatty acid ester, sodium laurylsulfonate, methylcellulose gum, ethyl cellulose etc.; Disintegration inhibitor, for example sucrose, Tristearoylglycerol, theobroma oil, hydrogenation wet goods; Absorption enhancer, for example quaternary ammonium salt, sodium lauryl sulphate etc.; Lubricant, for example talcum powder, silicon-dioxide, W-Gum, stearate, boric acid, whiteruss, polyoxyethylene glycol etc.Tablet further can also be made coating tablet, for example sugar coated tablet, thin membrane coated tablet, ECT, or double-layer tablets and multilayer tablet.

For example, can be extensive use of various carrier well known in the art for pill is made in the administration unit.Example about carrier is, for example thinner and absorption agent are as glucose, lactose, starch, theobroma oil, hydrogenated vegetable oil, polyvinylpyrrolidone, Gelucire, kaolin, talcum powder etc.; Tackiness agent is as gum arabic, tragacanth gum, gelatin, ethanol, honey, liquid sugar, rice paste or batter etc.; Disintegrating agent is as agar powder, dry starch, alginates, sodium laurylsulfonate, methylcellulose gum, ethyl cellulose etc.

For example for capsule is made in the administration unit, the effective constituent The compounds of this invention is mixed with above-mentioned various carriers, and the mixture that will obtain thus places hard gelatine capsule or soft capsule.Also the effective constituent The compounds of this invention can be made microcapsule, be suspended in and form suspensoid in the aqueous medium, in the hard capsule of also can packing into or make injection and use.

For example, The compounds of this invention is made injection preparation, as solution, suspensoid solution, emulsion, lyophilized injectable powder, this preparation can be moisture or non-water, can contain acceptable carrier, thinner, tackiness agent, lubricant, sanitas, tensio-active agent or dispersion agent on a kind of and/or multiple pharmacodynamics.Can be selected from water, ethanol, polyoxyethylene glycol, 1 as thinner, the isooctadecanol of ammediol, ethoxylation, the isooctadecanol of polyoxyization, Polyoxyethylene Sorbitol Fatty Acid Esters etc.In addition, ooze injection liquid, can in injection preparation, add proper amount of sodium chloride, glucose or glycerine, in addition, can also add conventional solubility promoter, buffer reagent, pH regulator agent etc. in order to prepare etc.These auxiliary materials are that this area is commonly used

In addition, as needs, also can in pharmaceutical preparation, add tinting material, sanitas, spices, correctives, sweeting agent or other material.

For reaching the medication purpose, strengthen result of treatment, medicine of the present invention or pharmaceutical composition can be with any known medication administrations.

The dosage of The compounds of this invention pharmaceutical composition depends on many factors, for example to prevent or treat the character and the severity of disease, the sex of patient or animal, age, body weight, personality and individual reaction, route of administration, administration number of times, therapeutic purpose, therefore therapeutic dose of the present invention can have large-scale variation.In general, the using dosage of Chinese materia medica composition of the present invention is well known to a person skilled in the art.Can be according to the actual drug quantity that is contained in the preparation last in the The compounds of this invention composition, in addition suitable adjustment to reach the requirement of its treatment significant quantity, is finished prevention of the present invention or therapeutic purpose.The consumption of the suitable dose scope compound of the present invention of the every day of The compounds of this invention is the 0.001-150mg/Kg body weight, is preferably the 0.01-100mg/Kg body weight, and more preferably the 0.01-60mg/Kg body weight most preferably is the 0.1-10mg/Kg body weight.Above-mentioned dosage can the single dose form or be divided into several, for example two, three or four dosage form administrations this be subject to administration doctor's clinical experience and comprise the dosage regimen of using other treatment means.

Each treats that required total dose can be divided into repeatedly or by the dose administration.Compound of the present invention or composition can be taken separately, or merge use and adjust dosage with other treatment medicine or symptomatic drugs.

Compound of the present invention has the effect that obvious promotion human embryo and brain neural stem cell clone forms in the test to human embryo and brain neural stem cell cloning efficiency, illustrates that compound of the present invention has the effect of senile nerve degenerative diseases of treatment such as senile dementia.

Compound of the present invention has the trend of rising neurocyte cytosolic free calcium level in to the test of the influence of neurocyte cytosolic free calcium.Calcium plays an important role in cellular activity as the second messenger, and the variation of cytosolic free calcium concentration and a lot of physiology/pathology stimulates and the reaction of cell internal effect device has substantial connection.

The compounds of this invention has tangible enhancement to the long time-histories enhancing of rat hippocampus (LTP) in to the test of the long time-histories enhancing of rat hippocampus (LTP), (P＜0.05vs control, n=5).The compounds of this invention has enhancement to the cynapse transmission of neurocyte basis, illustrates that compound of the present invention has nootropic effect.

Description of drawings

16 kinds of optical activity Clausenamides of Fig. 1 are to the influence of people's embryo stem cell of cranial nerve

Embodiment

Embodiment 1 light neoclausenamide (I alive ₂) preparation (seeing route 1)

The fractionation of racemization neoclausenamide ketone:

Racemization neoclausenamide ketone 2.7g, add to the dichloromethane solution of the 30mL of (-)-menthol oxygen Acetyl Chloride 98Min. for preparing by 2.7g (-)-menthol fluoroacetic acid, cool off with ice-water bath, add the 1.5mL pyridine then, stirring at room is to reacting completely, and reaction solution is with the methylene dichloride dilution of 50mL, successively with 2N hydrochloric acid, saturated sodium carbonate solution and salt washing, the organic layer anhydrous sodium sulfate drying.Get 6g oily matter after concentrating, add hexane and solidify, solid filtering gets 1.48g 3-O-[(-with recrystallizing methanol) menthol oxygen ethanoyl]-(3R, 4S, 5R)-and neoclausenamide ketone [ester (a)], mp:170-172 ℃, [α] _D ¹⁵=-50.9 (c, 1.25, CHCl ₃), yield 33.8%.The filtrate column chromatography obtains 3-O-[(-) menthol oxygen ethanoyl]-(3S, 4R, 5S)-and neoclausenamide ketone [ester (b)], mp:104-105 ℃, [α] _D ¹⁵=-31.2 (c, 1.40, CHCl ₃), yield 31.8%.Ester (a) and ester (b) boil off methyl alcohol respectively with the methanol solution hydrolysis of tosic acid, and resistates is dissolved in methylene dichloride, and solution is washed with alkali and aqueous acid successively, from 6g ester (a) obtain 3.25g (-)-(3R, 4S, 5R)-neoclausenamide ketone, yield 86%, mp:164-167 ℃, [α] _D ¹⁵=-14.9 (c, 0.60, CHCl ₃); 5.5g ester (b) obtain 3.0g (+)-(3S, 4R, 5S)-neoclausenamide ketone, yield 89%, mp:167-169 ℃, [α] _D ¹⁵=+14.1 (c, 0.54, CHCl ₃).

Light neoclausenamide (I alive ₂) obtain by the 3-O-tetrahydropyranyl ethers reduction of light neoclausenamide ketone alive.

The 10ml anhydrous tetrahydro furan liquid of (+)-3-O-THP trtrahydropyranyl neoclausenamide ketone 0.45g (1.19mmol) is injected into-the 2.5ml 1.0M LTBB/THF of 25--30 ℃ in, react after 1 hour, (contain 2ml, 30%H with the 40ml frozen water ₂O ₂) decompose, use dichloromethane extraction, close the And extracting solution, use 2N NaOH, saturated NaHCO3 and NaCl solution washing (PH ≈ 8) successively, no Shui Liu Suan Na drying, concentrate oily matter, with 3ml dehydrated alcohol and 25mg TSOHH2O, 60 ℃ were reacted 30 minutes, the 5ml that adds diethyl ether after cold slightly, continuous cold analysis goes out (+)-(3R, 4S, 5R, 6S)-neoclausenamide (I ₂), mp:186-187 ℃, [α] _D ¹⁸=+89.5 (c, 0.20, MeOH), yield 77.9%.

(-)-3-O-THP trtrahydropyranyl neoclausenamide ketone 0.379g (1.0mmol), the reduction of the same method go to protect (-)-(3S, 4R, 5S, 6R)-neoclausenamide (I ₂), mp:186-187 ℃, [α] _D ¹⁸=-88.6 (c, 0.18, MeOH), yield 77.4%.

Embodiment 2 light are lived and are shown neoclausenamide (I ₄) preparation

(+)-(3S, 4R, 5S)-and neoclausenamide ketone 1.05g (3.56mmol.), aluminum isopropylate 2.4g (11.75mmol.) is dissolved in the anhydrous anhydrous isopropyl alcohol of 30ml, heated and stirred, slowly steam Virahol and acetone, and constant speed drips anhydrous isopropyl alcohol simultaneously, and reaction in about 6.5 hours is finished, and steams and removes most of solvent, be chilled to room temperature and add 60ml water and 20ml 3N hydrochloric acid stirring at room, separate out a large amount of white solids, use recrystallizing methanol, get (-)-(3S, 4R, 5S, 6S)-the Biao neoclausenamide, yield 85%, m.p.217-219 ℃, [α] _D ²⁴=-36.5 (c, 0.128, MeOH).With methyl alcohol recrystallization once more, m.p.221-222 ℃, [α] _D ²⁰=-37.3 (c, 0.15, MeOH).

(-)-(3R, 4S, 5R)-and neoclausenamide ketone is raw material, the same operation, with the aluminum isopropylate reduction, get (+)-(3R, 4S, 5R, 6R)-and the Biao neoclausenamide, m.p.220-222 ℃, [α] _D ²⁰=+36.5 (c, 0.16, MeOH).

Embodiment 3 table Clausenamide (I ₃) preparation (seeing route 2)

A:(±)-Biao Clausenamide (I ₃) preparation

With (±)-(4R ^*, 5R ^*, 6R ^*)-3-deoxidation table Clausenamide (3-deoxidation I ₃) 90mg (0.032mmol.), with anhydrous THF of 2.5mL and 0.7mL hexamethylphosphoramide dissolving (N ₂Protection is down), be chilled to-70 ℃, stirred 5 minutes; the lithium diisopropylamine THF solution that adds 1mL (0.32mmol.) new system with syringe;-60 ℃ to-70 ℃ were stirred 1 hour down, added triethyl-phosphite 53ul, fed the O that handled through potassium hydroxide, the vitriol oil, Calcium Chloride Powder Anhydrous successively ₂Maintain the temperature at-60 ℃ to-70 ℃, stop ventilation after 2 hours, reaction solution is adjusted downward to pH value=3-4 with 0.5mol/L hydrochloric acid at ice-water bath, more successively with ethyl acetate wash, washing, sodium chloride aqueous solution wash anhydrous sodium sulfate drying, column chromatography obtains title compound 40mg behind the evaporating solvent, reclaim raw material 40mg, yield 40%, recrystallization mp:193-195 ℃.

B:(-)-(3S, 4R, 5R, 6R)-Biao Clausenamide (I ₃) and (+)-(3R, 4S, 5S, 6S)-Biao Clausenamide (I ₃) preparation

With (±)-3-deoxidation table Clausenamide (3-deoxidation I ₃) 600mg is dissolved in the 30mL anhydrous methylene chloride, again with O-acetyl-(-)-R-amygdalic acid 621mg, 4-(dimethylamino) pyridine 26mg and 1,3-dicyclohexyl carbimide 880mg adds successively, stirs 1 hour under the room temperature, the elimination insolubles, 20mL washed with dichloromethane filter cake, organic phase is washed till meta-acid with 2mol/L hydrochloric acid, washes with saturated sodium bicarbonate aqueous solution, saturated sodium-chloride water solution again, anhydrous sodium sulfate drying spends the night, and boils off solvent and gets oily matter 930mg.Silica gel H ethyl acetate: sherwood oil=1: 2.Purifying get (4R, 5R, 6R)-5-O-acetyl-R-mandeloyl-3-deoxidation table Clausenamide 452mg, yield 46%, mp:212-215 ℃; (4S, 5S, 6S)-and 5-(O-acetyl-R-mandeloyl)-O-3-deoxidation table Clausenamide 370mg, mp 206-209 ℃, yield 40%.

Will (4S, 5S, 6S)-5-(O-acetyl-R-mandeloyl)-O-3-deoxidation table Clausenamide 234mg is dissolved in 20mL methyl alcohol and the 10mL methylene dichloride, adds salt of wormwood 141mg, stirring at room 12 hours.With in the 2mol/L hydrochloric acid and back pressure reducing and steaming solvent, with the methylene dichloride dissolving, the washing back is washed once with saturated sodium-chloride water solution again, and anhydrous sodium sulfate drying, evaporating solvent get the 150mg solid.Column chromatography purification get (+)-(4S, 5S, 6S)-3-deoxidation table Clausenamide (3-deoxidation I ₃) 134mg, white solid, yield 93%.Mp:239-242 ℃ [α] ³⁰ _D=+137 (c, 0.465, methyl alcohol)

By the same method of last step reaction, will (4R, 5R, 6R)-5-O-acetyl-R-mandeloyl-3-deoxidation table Clausenamide is with K ₂CO ₃/ CH ₃OH handle obtain (-)-(4R, 5R, 6R)-3-deoxidation table Clausenamide (3-deoxidation I ₃), white solid, yield and last close, mp:237-240 ℃, [α] ³⁰ _D=-136 (c, 0.480, methyl alcohol).

With (-)-(4R, 5R, 6R)-3-deoxidation table Clausenamide (3-deoxidation I ₃) or (+)-(4S, 5S, 6S)-3-deoxidation table Clausenamide (3-deoxidation I ₃) be raw material, use racemization 3-deoxidation table Clausenamide (3-deoxidation I ₃) introduce the method for 3 hydroxyls, can obtain respectively (-)-(3S, 4R, 5R, 6R)-Biao Clausenamide (I ₃), mp:107-109 ℃, [α] ²⁹ _D=-204 (c, 0.445, methyl alcohol) or (+)-(3R, 4S, 5S, 6S)-Biao Clausenamide (I ₃), mp:108-110 ℃ [α] ²⁹ _D=+201 (c, 0.245, methyl alcohol).

Embodiment 4 is along Clausenamide (I ₅) preparation

Route 5 is along Clausenamide (I ₅) preparation

Acid sodium dichromate solution (0.7g sodium dichromate 99,0.7g the vitriol oil and 5mL water are made into) add to (+)-(3S, 4R, 5S) 10ml dichloromethane solution of neoclausenamide ketone of 0.25g, stirring at room 5 hours, add dichloromethane extraction, extracting solution with sodium hydrogen carbonate solution and washing, boils off solvent successively, residue gets 0.19g with recrystallizing methanol, yield 78%, mp:157-159 ℃, [α] _D ¹⁵=-199.6 (c, 0.75, CHCl ₃) (-)-(5S) Δ ^3,4-neoclausenamide ketone

(-)-(5S)-Δ ^3,4-neoclausenamide ketone 0.1 gram is dissolved in and contains 1ml acetic acid, and the 10ml methylene dichloride of 0.01mol sodium borohydride stirs, after following the tracks of reaction and finish with thin layer, splash into acetic acid, add the 20ml methylene dichloride then to decompose remaining sodium borohydride, reaction solution inclines to the 50ml frozen water, isolates organic layer, successively with saturated sodium bicarbonate aqueous solution and washing, steaming vibrating dichloromethane, residue post layer roll over (-)-(3S, 4S of 0.074g, 5S)-along Clausenamide ketone, yield 73%, mp:145-147 ℃, [α] _D ²⁰=-111.0 (C, 0.48, CHCl ₃).

(-)-(3S, 4S, 5S)-be dissolved in the 10ml methylene dichloride along Clausenamide ketone 0.08g, with 0.01g sodium borohydride/methyl alcohol reduction, after finishing, reaction adds the 30ml methylene dichloride, then with acetic acid treatment residue sodium borohydride, with sodium bicarbonate and washing, boil off solvent and get oily matter, with acetone and sherwood oil recrystallization, get (+)-(3S, 4S, 5S, 6R)-along Clausenamide (I ₅) crystal 0.59g, yield 77%, mp:197-199.5 ℃, [α] _D ²²=+6.30 (c, 0.46, CHCl ₃).

With (-)-(3R, 4S, 5R)-neoclausenamide ketone is raw material, react as stated above (+)-(5R)-Δ ^3,4-neoclausenamide ketone, yield 75%, m.p.154-156 ℃, [α] ¹⁵ _D=+206.8 (c, 0.90, CHCl ₃); (+)-(3R, 4R, 5R)-along Clausenamide ketone, yield 76%, m, p, 130-132 ℃, [α] _D ²⁰=+116.5 (c, 40, CHCl ₃); (-)-(3R, 4R, 5R, 6S)-along Clausenamide (I ₅), productive rate 69%, m, p, 196-198 ℃, [α] _D ²²=-6.07 (c, 0.67, CHCl ₃).

Embodiment 5 is along table Clausenamide (I ₇) preparation

R=-CO-R ' (R '=C ₁-C ₆), tetrahydropyrans, MEM[(2-methoxyl group-oxyethyl group)-methylene radical), MOM (methoxyl group methylene radical)

Route 6 is along table Clausenamide (I ₇) preparation

0.2 gram 6-O-acetyl table neoclausenamide is dissolved in the 20ml dichloromethane solvent, drips the acidic aqueous solution (Na of sodium dichromate 99 in batches ₂Cr ₂O ₇/ H ₂SO ₄=20mol/7mol) 5ml, stirring at room to raw material point disappears, and adds 20mlCH ₂Cl ₂Dilution, branch vibration layer, water and saturated sodium bicarbonate aqueous solution wash organic layer respectively, anhydrous sodium sulfate drying, boil off behind the solvent the light brown solid, post layer folding separates (CH ₂Cl ₂/ CH ₃OH 50/1) product 0.163g, mp:166.5-168 ℃, productive rate 65%.

Present method also is applicable to the synthetic of corresponding light live body.

By (+)-(3R, 4S, 5R, 6R)-the Biao neoclausenamide get (5R, 6R)-6-O-acetyl-Δ ^3,4-Biao Clausenamide, [α] _D ²²=+80.4 ° of (c, 0.47, CHCl ₃), mp:170-172 ℃, by (-)-(3S, 4R, 5S, 6S)-the Biao neoclausenamide get (5S, 6S)-6-O-acetyl-Δ ^3,4-Biao Clausenamide, [α] _D ²²=-83.4 ° of (c, 0.37, CHCl ₃), mp:168-170 ℃.

With 0.1g 6-O-acetyl-Δ ^3,4-Biao Clausenamide is dissolved in the 20mL methylene dichloride, drips Glacial acetic acid 0.5mL under the room temperature, adds the 0.2g sodium borohydride in batches, being stirred to raw material point disappears, add 20mL methylene dichloride dilution again, in the impouring 50mL frozen water, branch vibration layer after the stirred for several minute, organic layer washs 2 times with saturated sodium bicarbonate aqueous solution, anhydrous sodium sulfate drying, solvent evaporated obtains white solid, obtains white trichite 0.073g with ether/sherwood oil recrystallization, mp:128-130 ℃, yield 71%.

Present method is equally applicable to the synthetic of light live body, the raw material of living by light obtain respectively (+)-(3R, 4R, 5R, 6R)-6-O-acetyl is along table Clausenamide, mp:128-130 ℃, [α] _D ¹⁶=+13.8 (c, 0.50, CHCl ₃); (-)-(3S, 4S, 5S, 6S)-and the suitable table of 6-O-acetyl Clausenamide, mp:126-128 ℃, [α] _D ¹⁶=-14.3 (c, 0.43, CHCl ₃).

0.07g 6-O-acetyl is dissolved in the 10mL methyl alcohol along the table Clausenamide, add the 0.05g Anhydrous potassium carbonate, be stirred to raw material point under the room temperature and disappear, boil off most of solvent after, add the dilution of 30mL methylene dichloride, respectively with 0.1N hydrochloric acid, water and saturated sodium bicarbonate aqueous solution washing, anhydrous sodium sulfate drying boils off solvent and obtains white solid, obtains white thread solid 0.04g with acetone/sherwood oil recrystallization, mp:191-193 ℃, yield 65%.

Present method is equally applicable to the synthetic of light live body, and the raw material of being lived by light can obtain (-)-(3R, 4R, 5R, 6R) suitable table Clausenamide (I ₇), mp:197-199 ℃, [α] _D ¹⁵=-38.7 (c, 0.385, CHCl ₃); (+)-(5S is 6S) along table Clausenamide (I for 3S, 4S ₇), mp:199-202 ℃, [α] _D ¹⁶=+39.7 (c, 0.785, CHCl ₃).

Embodiment 6 is along neoclausenamide (I ₆) and along table neoclausenamide (I ₈) preparation

Route 7 is along neoclausenamide (I ₆) and along table neoclausenamide (I ₈) preparation

A: along the preparation of neoclausenamide ketone

Method one is with the suitable neoclausenamide ketone of method preparation of diethyl azodiformate/Mono Chloro Acetic Acid/triphen phosphorus transposition

The diethyl azodiformate (DEAD) of 2.10g mL is splashed into 1.5g (-)-(3R gradually, 4S, 5R)-neoclausenamide ketone, 2.6g in the chloroacetic toluene solution of triphen phosphorus and 0.99g, reaction solution at room temperature stirred 12 hours, the mixed solution that adds ethyl acetate and sherwood oil then filters, and filter cake washs with ethyl acetate, merging filtrate and washings, to boil off solvent after the washing, resistates at room temperature stirred 18 hours with the 3mL methanol solution of 750mg tosic acid, boiled off methyl alcohol, resistates is dissolved in methylene dichloride, organic layer is used sodium bicarbonate aqueous solution successively, saturated sodium-chloride water solution is washed, and boils off solvent, and resistates recrystallization after column chromatography for separation obtains 1.05g (-)-(3S, 4S, 5R)-along neoclausenamide ketone, mp:145.8-146.9 ℃, [α] _D ²⁵=-138.6 (c, 0.81, CHCl ₃).

With (+)-(3S, 4R 5S)-neoclausenamide ketone is raw material, as stated above, obtain (+)-(3R, 4R, 5S)-along neoclausenamide ketone, mp:143.8-145.7 ℃, [α] _D ²⁵=+139.8 (c, 1.74, CHCl ₃).

Method two is with the suitable neoclausenamide ketone of method preparation of cesium carbonate/crown ether transposition

Racemization neoclausenamide ketone 1g is dissolved in the 10mL anhydrous pyridine, the ice-water bath cooling adds the 0.42g methylsulfonyl chloride down, at room temperature be stirred to then and react completely, add 50mL methylene dichloride dilute reaction solution, with the dilute hydrochloric acid neutralization, washing then, anhydrous sodium sulfate drying, boil off solvent and obtain resistates 1.18g, yield 94%.

Get above-mentioned sulphonate 0.5g and be dissolved in the 30mL dry-out benzene, add 4.1g cesium acetate and 2.4g dibenzoyl-hexaoxacyclooctadecane-6-6, the heating backwash is to reacting completely, and cooling concentration is removed benzene, and column chromatography gets 3-O-acetyl along neoclausenamide ketone 0.39g, oily matter, yield 87%.

Be dissolved in the 40mL methyl alcohol along neoclausenamide ketone 0.27g with above-mentioned 3-O-acetyl, add tosic acid 118mg, the heating backwash boils off methyl alcohol to reacting completely, and resistates is dissolved in methylene dichloride, successively with saturated sodium bicarbonate, the saturated common salt aqueous solution is washed, and anhydrous sodium sulfate drying concentrates and obtains solid 0.21g yield 89%, recrystallization from ethyl acetate/petroleum ether obtains racemization along neoclausenamide ketone, mp:189.3-192.4 ℃.

This law is that raw material obtains light suitable neoclausenamide ketone alive with light neoclausenamide ketone alive, and the result is identical with method one.

B: along the suitable table of neoclausenamide ketone reduction preparation neoclausenamide (I ₈)

The preparation of the suitable neoclausenamide of racemization:

0.15g (0.5mmol) (±) is dissolved in the 20ml methyl alcohol along neoclausenamide ketone, stir and add 0.41g (1.1mmol) sodium borohydride down in batches, stirring at room 3 hours, TLC (ethyl acetate/petroleum ether=2: 1) monitoring raw material point disappears, and Rf value 0.26 and 0.33 liang of dot generation are arranged, and neutralizes with acetic acid, and be poured in the 50mlCH2Cl2/20ml frozen water stirring liquid, tell organic layer then, respectively water, Eat and NaHCO3 washing, anhydrous Na 2SO4 drying, steaming desolventize white solid 0.134g, the post layer separates, and component (±) is along neoclausenamide 0.04g, yield 26.5% before getting, use the ether recrystallization, get white filament crystal, m.p164.5-166 ℃ and the new Calusena lansium acyl 0.075g of the suitable table of back component (±), yield 49.7%, recrystallizing methanol gets white platelet, m.p252-254 ℃

Light is lived along the preparation of neoclausenamide:

With 250mg (+)-3R, 4R, 5S-is a raw material along neoclausenamide ketone, sodium borohydride reduction is used in the same operation, get (+)-(3R, 4R, 5S, 6R)-along neoclausenamide 73mg, yield 29%, m.p164.5-166 ℃, [α] _D ²⁰=+66.7 (c, 0.525, MeOH); Also obtain 3R simultaneously, 4R, 5S, the suitable table of 6S-neoclausenamide 132mg, yield 52.45%, m.p248-250 ℃, [α] D22+19.2 (c, 0.525, MeOH)

With 250mg (-)-3S, 4S, 5R-is a raw material along neoclausenamide ketone, sodium borohydride reduction is used in the same operation, get (-)-(3S, 4S, 5R, 6S)-along neoclausenamide 67mg, yield 26.6%, m.p168-170 ℃, [α] _D ²²=-65.3 (c, 0.32, MeOH); Also obtain simultaneously (-)-(3S, 4S, 5R, 6R)-along table neoclausenamide 134mg, yield 53.24%m.p250-252 ℃, [α] _D ²²=-20.75 (c, 0.265, MeOH)

Above-mentioned (-)-(3S, 4S, 5R)-be dissolved in the 5mL aluminum isopropylate along neoclausenamide ketone 100mg, add the 160mg aluminum isopropylate, in 100 ℃ oil bath, heat, stir and steam Virahol and acetone, and constant speed is added anhydrous isopropyl alcohol, lasting a few hours afterreactions finishes, boil off most of Virahol, add water to decompose aluminum isopropylate, with the hcl acidifying of 6N, the platelet of 90mg is separated out in the ice-water bath cooling, and thin-layer chromatography shows in the product along table neoclausenamide (I ₈) and along neoclausenamide (I ₆) ratio be about 3/1, total recovery 90%, with recrystallizing methanol obtain (-)-(3S, 4S, 5R, 6R)-along table neoclausenamide (I ₈), mp:271.1-273 ℃, [α] _D ³⁰=-33.3 (c, 0.34, DMSO)

With (+) (3R, 4R, 5S)-be raw material along neoclausenamide ketone, as stated above reduction can obtain (+)-(3R, 4R, 5S, 6S)-along table neoclausenamide (I ₈), mp:275-277 ℃, [α] _D ³⁰=+31.2 (c, 0.31, DMSO)

The constant of 16 light of table two Calusena lansium acid amides isomer alive

Numbering	The isomer title	Absolute configuration	?Mp℃	[α] t D(c, solvent)
					I 1	(+) Clausenamide	3R，4S，5S，6R	?161-162	+144(0.26，MeOH)
(-) Clausenamide	3S，4R，5R，6S	?161-162	-146(0.21，MeOH)
				I 2		(+) neoclausenamide	3R，4S，5R，6S	?186-187	+89.5(0.2，MeOH)
(-) neoclausenamide	3S，4R，5S，6R	?186-187	-88.6(0.18，MeOH)
					I 3	(+) table Clausenamide	3R，4S，5S，6S	?108-110	+201(0.245，MeOH)
(-) table Clausenamide	3S，4R，5R，6R	?107-109	-204(0.445，MeOH)
				I 4		(+) table neoclausenamide	3R，4S，5R，6R	?220-222	+36.5(0.15，MeOH)
(-) table neoclausenamide	3S，4R，5S，6S	?221-222	-37.7(0.16，MeOH)
					I 5	(+) is along Clausenamide	3S，4S，5S，6R	?197-199	+6.30(0.46，CHCI 3)
(-) is along Clausenamide	3R，4R，5R，6S	?196-198	-6.07(0.675，CHCI 3)
				I 6		(+) is along neoclausenamide	3R，4R，5S，6R	?164-166	+66.7(0.46?MeOH)，
(-) is along neoclausenamide	3S，4S，5R，6S	?168-170	-65.3(0.32，MeOH)
					I 7	(+) is along the table Clausenamide	3S，4S，5S，6S	?198-199	+39.7(0.785，CHCI 3)
(-) is along the table Clausenamide	3R，4R，5R，6R	?199-202	-38.7(0.385，CHCI 3)
				I 8		(+) is along the table neoclausenamide	3R，4R，5S，6S	?275-277	+31.2(0.31，DMSO)
(-) is along the table neoclausenamide	3S，4S，5R，6R	?271-273	-33.3(0.34，DMSO)

Pharmacological evaluation

Experimental example 1 The compounds of this invention is to the influence of human embryo and brain neural stem cell cloning efficiency

Purpose and meaning:

The increase of neural stem cell quantity or life-time dilatation are to increasing neurone and preventing that neuron loss has the meaning of particularly important.Whether the specific culture that we set up the human embryo and brain neural stem cell has the effect that promotes cell proliferation of nerve cord in conjunction with 16 light of method detection Clausenamide isomer alive that cell clone forms.

Method:

The human embryo and brain neural stem cell is at the DMEM/F12 substratum (purchasing the company in BIBCO) that contains Urogastron (EGF) 20ng/ml, Prostatropin (FGF-2) 20ng/ml, N-2 additive with at 5%CO ₂With cultured continuously in 37 ℃ of incubators.With 0.1% trypsin solution the neural ball of human embryo and brain neural stem cell is digested to single cell suspension, centrifugal 1000rpm * 5min, again with the substratum flushing, cell in being inoculated in 96 well culture plates, neural stem cell 1 * 10 ³Cells/well, every group 4 hole, cultured continuously.Dosing behind the 24h, the dosage of 16 kinds of optically active Clausenamide isomer (the No.1-No.16 title sees Table 1) is 1 μ M, change the low nutritional medium (the DMEM/F12 substratum of FGF-22ng/ml, EGF 2ng/ml and N-2 additive) of a pastille weekly, twice in microscopically observation cell growth state weekly, in the 3rd week, in 4 weeks, 6 weeks at microscopically counting cells clone number, were carried out statistical procedures with the t check with control group respectively.

The results are shown in Table 1 and accompanying drawing 1

The influence that table 1-A.16 kind compound forms human embryo and brain neural stem cell clone

Numbering	The compound title	????N	Dosage	3 weeks	4 weeks	6 weeks
										???μM	Clone's number Mean ± SD	Clone's number Mean ± SD	Clone's number Mean ± SD
	Contrast (DMSO)	????4	????0	43.00±4.97	?30.33±4.99	?22.25±4.86
							????I 2	(-) neoclausenamide	????4	????1	53.00±6.71	?37.50±4.15	?24.5±4.43
(+) neoclausenamide	????4	????1	49.00±8.86	?39.75±7.50	?30.00±4.40*
						????I 4		(-) table neoclausenamide	????4	????1	58.0±13.02	?36.75±7.59	?32.50±7.05*
(+) table neoclausenamide	????4	????1	49.75±10.26	?38.50±5.02	?26.00±2.94
							????I 6	(-) is along neoclausenamide	????4	????1	49.50±5.43	?35.25±7.46	?33.50±4.20#
(+) is along neoclausenamide	????4	????1	47.00±9.03	?42.50±10.01	?24.00±4.69

●p＜0.05(single?tail?T?test)；#p＜0.05(double?tail?T?test)

The influence that table 1-B. The compounds of this invention forms human embryo and brain neural stem cell clone

Code name	Compound	????N	Dosage μ M	The 6th week clone forms number	Cell clone rate of formation %
						????DMSO	Control group	????4	??1	?22.25±4.86	??100
????I 1	(+) Clausenamide	????4	??1	?27.00±5.48	??121.35
						(-) Clausenamide	????4	??1	?26.50±4.12	??119.1
	????I 2	(+) neoclausenamide	????4	??1	?30.00±4.40 *						??134.83
(-) neoclausenamide						????4	??1	?24.5±4.43	??110.11
		????I 3	(-) table Clausenamide	????4	??1					?25.00±3.16	??112.36
(+) table Clausenamide	????4					??1	?28.75±3.59	??129.21
			????I 4	(+) table neoclausenamide	????4				??1	?26.00±2.94	??116.85
(-) table neoclausenamide	????4	??1				?32.50±7.05 *	??146.07
				????I 5	(+) is along Clausenamide			????4	??1	?23.75±6.70	??106.74
(-) is along Clausenamide	????4	??1	?24.50±3.11			??110.11
					????I 6		(+) is along neoclausenamide	????4	??1	?24.00±4.69	??107.87
(-) is along neoclausenamide	????4	??1	?33.5±4.20#	??150.56

????I 7	(+) is along the table Clausenamide	????4	??1	?23.00±0.82	??103.37
						(-) is along the table Clausenamide	????4	??1	?29.25±6.85	??131.46
	????I 8	(+) is along the table neoclausenamide	????4	??1	?27.50±5.26						??123.60
(-) is along the table neoclausenamide						????4	??1	?25.00±3.56	??112.36

● ^*P＜0.05；#P＜0.01。

Conclusion: in 16 kinds of optical activity Clausenamide isomer of the present invention three kinds of Clausenamide (isomer I are arranged ₂((+) neoclausenamide)); I ₄((-) table neoclausenamide) and I ₆((-) is along neoclausenamide) has the effect that obvious promotion human embryo and brain neural stem cell clone forms, and this has the meaning of particularly important to senile nerve degenerative diseases such as senile dementia etc.

Experimental example 2, compound are to the influence of neurocyte cytosolic free calcium

Purpose and meaning

Calcium plays an important role in cellular activity as the second messenger, the variation of cytosolic free calcium concentration is the hinge between the many physiology of contact/pathology stimulation and the reaction of cell internal effect device, and compound has significance to the influence of cytosolic free calcium concentration in drug screening.

Method

Get neonate rat, separate the pallium neurocyte, preparation single cell suspension 10 ⁶Cell/ml, under 37 degree conditions, cell is through fluorescent probe (Fura-2/AM, purchase company in SIGMA) 5 μ M dosage carry out load 40min, in Japanese SHIMADZU RF-5000 fluorodensitometric determination instrument, measure the fluorescence intensity of intracellular calcium, when tranquillization and added 37 ℃ of incubations of medicine 5 minutes, and the post-stimulatory cytosolic free calcium concentration of 50mM KCl, cytosolic free calcium rising amplitude after calculating dosing respectively 5 minutes and adding KCl, every kind of compound repeats to be (N=5～8) 5-8 time, and joint account as a result goes out the endocellular liberation calcium concn of each compound.

The results are shown in Table 2

Table 2.16 compound is to the influence of neurocyte cytosolic free calcium

The compound code name	16 kinds of Clausenamide Chinese names	????(％basal?level) ????X±SD(n＝5-8)
			Control group	????DMSO	????17.82±3.84
Control group	????KCl	????67.58±6.48
			I 1	(+) Clausenamide	????22.05±3.84
	????KCl	????60.99±10.32
			I 1	(-) Clausenamide	????20.99±4.91
	????KCl	????66.35±9.38
			I 2	(+) neoclausenamide	????26.39±3.39
	????KCl	????69.99±9.05
			I 2	(-) neoclausenamide	????19.49±4.51
	????KCl	????59.82±8.32

????I 3	(-) table Clausenamide	????25.80±4.93
				????KCl	????65.53±9.08
????I 3	(+) table Clausenamide	????17.79±3.40
				????KCl	????58.72±7.50
????I 4	(+) table neoclausenamide	????16.79±6.13
				????KCl	????70.60±7.94
????I 4	(-) table neoclausenamide	????16.79±6.13
				????KCl	????70.60±7.94
????I 5	(+) is along Clausenamide	????20.13±4.94
				????KCl	????65.13±15.48
????I 5	(-) is along Clausenamide	????17.85±4.97
				????KCl	????55.69±7.43
????I 6	(+) is along neoclausenamide	????14.09±5.81
				????KCl	????55.22±8.04
????I 6	(-) is along neoclausenamide	????23.64±4.96
				????KCl	????76.40±12.76
????I 7	(+) is along the table Clausenamide	????18.82±3.53
				????KCl	????65.52±7.28
????I 7	(-) is along the table Clausenamide	????22.80±4.30
				????KCl	????65.67±6.99
????I 8	(+) is along the table neoclausenamide	????15.86±5.55
				????KCl	????50.71±10.70
????I 8	(-) is along the table neoclausenamide	????25.90±5.54
				????KCl	????64.16±7.97

6 Clausenamide (I are arranged in the compound of the present invention ₁(+) Clausenamide); (I ₂(+) neoclausenamide); (I ₃(-) table Clausenamide); (I ₆(-) is along neoclausenamide); (I ₇(-) is along the table Clausenamide); (I ₈(-) is along table neoclausenamide) trend of rising cytosolic free calcium level arranged.Calcium plays an important role in cellular activity as the second messenger, and the variation of cytosolic free calcium concentration and a lot of physiology/pathology stimulates and the reaction of cell internal effect device has substantial connection.

Experimental example 3 The compounds of this invention strengthen the influence of (LTP) to the long time-histories of rat hippocampus

Purpose and meaning

Clausenamide shows tangible nootropic effect in multiple study of behaviour experiment, but its influence to the cynapse transduction activity is not clear at present, and cynapse is the basic link that iuntercellular information is transmitted and processed in the neural system, change on its functional activity and the morphological structure is learning and memory active neurobiology basis, therefore, this experiment adopts the electrophysiology technology from the cynapse level nootropic effect of Clausenamide to be studied.

Method

Adult male SD rats (5/group) is with 20% (w/v) urethane (1.0gkg ^-1, ip) anaesthetize and be fixed on the stereotaxic instrument.With reference to Pellegrino rat brain stereotaxic atlas, bury recording electrode (outer insulating layer coating, most advanced and sophisticated exposed 0.2mm, the stainless steel needle of diameter 0.2mm) at the hippocampal dentate granular cell layer.Tricorn gives 4 couple shown in the table 9 optically active Clausenamide.Stimulating electrode (two pieces of spacing 0.5mm cover the teflon insulation layer outward, most advanced and sophisticated exposed 0.2mm, the stainless steel needle of diameter 0.15mm constitutes) (perforant path is PP) between the fiber to be imbedded at rat entorhinal area break-through road.Electronic stimulator transfers to PP through stimulation isolator and stimulating electrode after producing the galvanism that continues.Adjust the position of stimulating electrode, up to observing typical excitatory postsynaptic potential (EPSP) (EPSP).After electric current amplifies by amplifier, through computer DataWave software processes.Stimulus intensity then adopts and causes maximum cluster spike potential (Populationspike, PS) 1/2 of required stimulus intensity.In whole experiment, give one time the testing stimulus frequency per 30 seconds, (Population spike amplitude PSA), calculates relative PSA percentage according to formula (PSA/ basis range value) to collection of record spike potential amplitude.

The results are shown in Table 3

Table 3.16 kind of optical activity Clausenamide strengthens the result of (LTP) to the long time-histories of rat hippocampus

Code name	The Clausenamide title	LTP 15 minutesX±SD	??LTP 30 minutes??X±SD	??LTP 60 minutes??X±SD
					??I 1	(+) Clausenamide	90.6±0.3	??110.1±13.1	??106.4±4.1
(-) Clausenamide	131.8±0.4	??138.5±8.9	??158.1±4.2 *
				??I 2		(+) neoclausenamide	99.3±29.6	??70.9	??97
(-) neoclausenamide	81.8±14.0	??65.5±4.3
					??I 3	(-) table Clausenamide	97.8±21.7	??91.2±22.5	??117.3±22.5
(+) table Clausenamide	136.0±22.8	??147.5±15.0	??207.8±12.8 *
				??I 4		(+) table neoclausenamide	104.7±8.0	??94.7±10.3	??101.1±28.5
(-) table neoclausenamide	90.6±11.9	??91.9±15.2	??118.2±15.4
					??I 5	(+) is along Clausenamide	87.3±4.4	??102.9±5.9	??122.5±14.5
(-) is along Clausenamide	126.2±2.3	??141.2±8.6	??205.4±24.7 *
				??I 6		(+) is along neoclausenamide	135.0±12.9	??150.9±19.9	??192.3±22.4 *
(-) is along neoclausenamide	94.1±6.7	??98.2±6.6	??94.9
					??I 7	(+) is along the table Clausenamide	101.7±5.2	??109.7±11.7	??109.6
(-) is along the table Clausenamide	107.2	??100.3	??105.4
				??I 8		(+) is along the table neoclausenamide	97.0±18.9	??110.1±25.7	??121.7±37.1
(-) is along the table neoclausenamide	88.5±10.2	??88.1±9.4	??84.6

Conclusion has 4 kinds of Clausenamide isomer ((I by experimental result (expression) as can be known in 16 kinds of optical activity Clausenamides of the present invention isomer ₆(+) is along neoclausenamide); (I ₅(-) is along Clausenamide); (I ₁(-) Clausenamide); (I ₃(+) table Clausenamide)) the long time-histories of rat hippocampus is strengthened (LTP) and have tangible enhancement, (P＜0.05vs control, n=5).The compounds of this invention has enhancement to the cynapse transmission of neurocyte basis, illustrates that compound of the present invention has nootropic effect.

Claims (5)

1. As shown in the general formula (I), the photoactive stereoisomer compound of xanthamide It is characterized by: I ₂ (3R, 4S, 5R, 6S) (+) neobantamide (3S, 4R, 5S, 6R) (-) Neobantamide I ₃ (3R, 4S, 5S, 6S) (+) epibantamide (3S, 4R, 5R, 6R) (-) Epibantamide I ₄ (3R, 4S, 5R, 6R) (+) represents neobantamide (3S, 4R, 5S, 6S) (-) means Neobantamide I ₅ (3S, 4S, 5S, 6R) (+) cisbantamide (3R, 4R, 5R, 6S) (-) Cisbantamide I ₆ (3S, 4S, 5S, 6S) (+) cis-epipanthamide (3R, 4R, 5R, 6R) (-) cis-epipanthamide I ₇ (3R, 4R, 5S, 6R) (+) cis neobantamide (3S, 4S, 5R, 6S) (-) cis neobantamide I ₈ (3R, 4R, 5S, 6S) (+) cis-epidemic neobantamide (3S, 4S, 5R, 6R) (-) Neobantamide 2. The preparation method of optically active stereoisomer compounds I ₂ , I ₄ , I ₅ , I ₆ , I ₇ and I ₈ according to claim 1, characterized in that it comprises the following steps Route 1 in: (a) Base-catalyzed cyclization: NaOCH ₃ , (CH ₃ ) ₄ NOH or lithium diisopropylamide (LDA) can be used; (b) Resolving agent: (-)-menthol oxyacetyl chloride, N-protected amino acid chloride; (c) Protection of hydroxyl, dihydropyran, acetyl chloride/pyridine or acetic anhydride/pyridine; (d) reducing agent for reducing C6 ketone: NaBH ₄ or L-selectride; (e) reducing agent for reducing C6 ketones: Al(iC ₃ H ₇ O) ₃ ; (f) Oxidizing agent for C ₃ -OH: K ₂ Cr ₂ O ₇ /H ⁺ , or KMnO ₄ +CuSO ₄ , MnO ₂ orDMSO/(COCl) ₂ ; (g) reducing agent for reducing Δ ^3,4 double bond: NaBH ₄ /H ⁺ , NaBH ₄ /AlCl ₃ or catalytic hydrogenation; (h) Configuration inversion of C ₃ -OH, with diisopropyl azocarboxylate (DIAD) or diethyl azocarboxylate (DEAD)/TPP, H ⁺ (Mitsunobu method) or with CsOAc/18-crown Ether-6 complete; This route uses the known racemic or photoactive N-methyl-N-benzoyl-3-phenylglycidylamide (A) as raw material. If the photoactive compound A is used as the raw material, step 2(b) resolution can be omitted. 3. The method for preparing the optically active stereoisomer compound I ₃ (C6 epimer epibantamide) according to claim 1, characterized in that it comprises the following steps

Route 2 Racemic 3-deoxyepixanthamide (3-deoxy-I ₃ ) is introduced into the C3 hydroxyl group to obtain racemic epixanthamide (I ₃ ); or firstly split to obtain the photoactive body of 3-deoxy-I ₃ , and then introduce hydroxyl to obtain photoactive epixanthamide (I ₃ ); (1) The 3-position hydroxyl group is introduced into 3-deoxyepixanthamide (3-deoxy-I ₃ ), and the conditions used are selected from lithium diisopropylamide (LDA)/O ₂ /triethyl phosphite Ester (P(OEt) ₃ )/hexamethylphosphoramide (HMPT)/THF; (2) Resolution of 3-deoxyepixanthamide (3-deoxy-I ₃ ), the resolution agent is selected from O-acetyl-R-mandelic acid, O-acetyl-S-mandelic acid, menthol oxygen Acetic acid, N-protected amino acids; (3) The condition of K ₂ CO ₃ /CH ₃ OH is used for the hydrolysis resolution agent. 4. A pharmaceutical composition, characterized by comprising an effective dose of any compound as claimed in claim 1 and a pharmaceutically acceptable carrier. 5. The application of the compound as claimed in claim 1 in the preparation of nootropic and anti-aging drugs.

Images